Posted by Michael Wonder on 07 Aug 2023
HuidaGene Therapeutics receives FDA rare paediatric disease designation for HG004 to treat inherited blindness
7 August 2023 - HG004 is a one time, direct to RPE treatment of inherited retinal disease caused by mutations in the RPE65 gene.
HuidaGene Therapeutics today announced the US FDA had granted rare paediatric disease designation to HG004 for the treatment of inherited retinal disease caused by RPE65 mutations.
